Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature.
Clicks: 313
ID: 108009
2020
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
4.2
/100
14 views
14 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Cefiderocol is a new siderophore cephalosporin with activity against carbapenem-resistant gram-negative bacteria. Data on its clinical efficacy are limited to complicated urinary tract infections. We present a series of 3 patients successfully treated with cefiderocol for complicated health care-associated infections and review published case reports.
| Reference Key |
zingg2020cefiderocolopen
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Zingg, Sandra;Nicoletti, G Jacopo;Kuster, Sabine;Junker, Milena;Widmer, Andreas;Egli, Adrian;Hinic, Vladimira;Sendi, Parham;Battegay, Manuel;Bättig, Veronika;Khanna, Nina;Tschudin-Sutter, Sarah; |
| Journal | Open forum infectious diseases |
| Year | 2020 |
| DOI |
10.1093/ofid/ofaa185
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.